SCHEMBL2877335

SCHEMBL2877335

CCS(=O)(=O)N1CCCc2cc(Br)ccc21

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
GAA P10253 2/20 0.51
HTR6 P50406 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
TP53 P04637 4/20 0.45
RORC P51449 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PDK1 Q15118 1/20 0.42
PDK2 Q15119 1/20 0.42
PDK3 Q15120 1/20 0.42
PDK4 Q16654 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2880232 0.91 MAPT (0.62) MAPTGAAMEN1KMT2ACYP11B1
SCHEMBL2882066 0.90 HTR6 (0.47) MAPTGAAHTR6MEN1KMT2A
SCHEMBL2880384 0.85 MEN1 (0.53) MAPTHTR6MEN1KMT2ACYP11B1
SCHEMBL2882290 0.81 MAPT (0.53) MAPTGAAMEN1KMT2ACYP11B1
SCHEMBL15101536 0.80 GAA (0.64) MAPTGAATP53
SCHEMBL14498366 0.78 L3MBTL1 (0.57) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL18363030 0.78 TP53 (0.62) MAPTHTR6MEN1KMT2ACYP11B1
SCHEMBL23128840 0.75 HSD17B3 (0.52) MAPTGAAHTR6MEN1KMT2A
SCHEMBL288153 0.75 NPC1 (0.62) GAAMEN1KMT2ACYP11B1CYP11B2
SCHEMBL10192150 0.74 CYP11B1 (0.56) MAPTGAACYP11B1CYP11B2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234422-A1 Sulfonylated Heterocycles Useful for Modulation of the Progesterone Receptor WYETH LLC (US) 2010-09-16 US disclosed
US-7750038-B2 Sulfonylated heterocycles useful for modulation of the progesterone receptor WYETH LLC (US) 2010-07-06 US disclosed
EP-2121657-A1 SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR Wyeth (US) 2009-11-25 EP disclosed
WO-2008109056-A1 SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR WYETH (US) 2008-09-12 WO disclosed
US-20080221160-A1 SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR WYETH (US) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221160-A1 SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR GNRHR, FSHR, PRLHR MAPT 4879/4885GAA 4872/4885HTR6 979/4885
US-20100234422-A1 Sulfonylated Heterocycles Useful for Modulation of the Progesterone Receptor GNRHR, FSHR, PRLHR MAPT 4879/4885GAA 4872/4885HTR6 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.